Global | January 2026 — Gilead Sciences, Inc. strengthened its innovation-led growth profile in 2025 through a focused set of regulatory approvals and commercial launches across HIV, oncology, and liver disease, reinforcing its long-term strategy centered on durable franchises, specialty pricing, and scientific leadership. These 2025 milestones mark a transition from portfolio rebuilding to execution-driven expansion heading into 2026.
HIV Portfolio: Long-Acting and Lifecycle Innovation
SUNLENCA® (lenacapavir) — HIV Treatment and Prevention
Condition: HIV infection (long-acting capsid inhibitor)
In 2025, Gilead advanced commercial rollout and market expansion of SUNLENCA following regulatory milestones, positioning it as a foundational long-acting therapy within the HIV treatment and prevention landscape.
Strategic Impact:
SUNLENCA supports Gilead’s ambition to reshape HIV care beyond daily oral regimens, strengthening long-term franchise durability and differentiation.
BIKTARVY® — HIV-1
Condition: HIV-1 infection
Gilead continued global market expansion and guideline-driven adoption of BIKTARVY during 2025, reinforcing its role as a backbone single-tablet regimen.
Strategic Impact:
BIKTARVY remains a cash-generating anchor, funding pipeline reinvestment while defending market share amid increasing competition.
Oncology Portfolio: Expanding ADC Leadership
TRODELVY® — Breast and Solid Tumors
Conditions: Metastatic triple-negative breast cancer and other solid tumors
In 2025, TRODELVY advanced through new regulatory approvals and commercial launches across additional geographies and treatment settings, strengthening Gilead’s position in antibody–drug conjugates (ADCs).
Strategic Impact:
Oncology diversification reduces Gilead’s historical dependence on antivirals while opening multi-billion-dollar growth pathways in solid tumors.
Liver Disease: Specialty and Global Health Focus
HEPATITIS Portfolio — Chronic Viral Hepatitis
Conditions: Hepatitis B and C
Gilead sustained new product introductions and access expansion in 2025 across international markets, supporting its leadership in chronic viral liver disease management.
Strategic Impact:
Liver disease franchises provide predictable, long-cycle revenues and support Gilead’s global health commitments.
Commercial and Scientific Enablement
Across its 2025 launches, Gilead increasingly leveraged:
- AI-enabled clinical trial optimization
- Data-driven launch sequencing
- Advanced real-world evidence platforms
These capabilities improved time-to-scale for newly approved products and enhanced lifecycle planning.
Looking Ahead: 2026 and Beyond
Gilead enters 2026 with:
- A modernized HIV franchise
- Growing momentum in oncology innovation
- A disciplined approach to capital allocation and R&D productivity
The company’s 2025 approvals and launches are expected to act as strategic growth levers, supporting sustained expansion while preserving scientific leadership.
Conclusion
Gilead’s 2025 execution reflects a clear strategic reset — leveraging long-acting innovation, oncology expansion, and disciplined commercialization. As these newly launched and approved therapies mature, Gilead is positioned to translate scientific leadership into durable shareholder and patient value beyond 2026.
By